Ownership Capital B.V. Sells 200,754 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ownership Capital B.V. cut its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,792,265 shares of the medical research company’s stock after selling 200,754 shares during the quarter. Edwards Lifesciences comprises 7.6% of Ownership Capital B.V.’s portfolio, making the stock its 2nd biggest position. Ownership Capital B.V. owned about 0.47% of Edwards Lifesciences worth $206,711,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC boosted its holdings in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 26,489 shares of company stock worth $2,002,829. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Robert W. Baird reduced their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Finally, Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $74.73 on Thursday. The stock has a market capitalization of $44.07 billion, a P/E ratio of 10.72, a P/E/G ratio of 4.92 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50-day moving average price of $72.84 and a two-hundred day moving average price of $69.82.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.